These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21859514)

  • 1. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal.
    Singh SP; Singh V; Kar N
    Int J Neuropsychopharmacol; 2012 Apr; 15(3):417-28. PubMed ID: 21859514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
    Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR
    Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine.
    Montgomery SA; Kasper S
    Int Clin Psychopharmacol; 2007 Sep; 22(5):283-91. PubMed ID: 17690597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agomelatine treatment of major depressive disorder.
    Dolder CR; Nelson M; Snider M
    Ann Pharmacother; 2008 Dec; 42(12):1822-31. PubMed ID: 19033480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression.
    Stein DJ; Picarel-Blanchot F; Kennedy SH
    Hum Psychopharmacol; 2013 Mar; 28(2):151-9. PubMed ID: 23532747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control.
    Kasper S; Corruble E; Hale A; Lemoine P; Montgomery SA; Quera-Salva MA
    Int Clin Psychopharmacol; 2013 Jan; 28(1):12-9. PubMed ID: 23023074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of agomelatine in previously-treated depressed patients.
    Kasper S; Hajak G
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):814-21. PubMed ID: 23820051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical studies on the efficacy of agomelatine on depressive symptoms.
    Goodwin GM
    CNS Drugs; 2009; 23 Suppl 2():35-9. PubMed ID: 19708724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agomelatine: new drug. Adverse effects and no proven efficacy.
    Prescrire Int; 2009 Dec; 18(104):241-5. PubMed ID: 20020562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies.
    Taylor D; Sparshatt A; Varma S; Olofinjana O
    BMJ; 2014 Mar; 348():g1888. PubMed ID: 24647162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
    Shu L; Sulaiman AH; Huang YS; Fones Soon Leng C; Crutel VS; Kim YS
    Asian J Psychiatr; 2014 Apr; 8():26-32. PubMed ID: 24655622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agomelatine: a narrative review.
    Demyttenaere K
    Eur Neuropsychopharmacol; 2011 Sep; 21 Suppl 4():S703-9. PubMed ID: 21835598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism, efficacy, and tolerability profile of agomelatine.
    MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
    Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
    J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.
    Kennedy SH; Grouin JM; Cadour S; Robert V; Picarel-Blanchot F
    Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29327372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerance profile of agomelatine and practical use in depressed patients.
    Rouillon F
    Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S31-5. PubMed ID: 16436938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
    Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
    Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA).
    Yeh TC; Kao LC; Tzeng NS; Kuo TB; Huang SY; Chang CC; Chang HA
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():60-7. PubMed ID: 26216863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.